Added to YB: 2026-01-30
Pitch date: 2026-01-22
NOVO-B.CO [bullish]
Novo Nordisk A/S
-18%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 391.60
Price Target
N/A
Dividend
3.68%
EV/EBITDA
8.73
P/E
11.60
EV/Sales
4.68
Sector
Pharmaceuticals
Category
turnaround
Show full summary:
The Curious Investor | An update & 8 new positions added in 2025 - New Position: Novo Nordisk A/S
NOVO-B.CO: Down 70% from peak on poor commercial execution vs Lilly, but obesity market in infancy. Novo's oral Wegovy shows higher weight loss than Lilly's pill yet analysts favor Lilly. CagriSema coming 2026 w/ 23% weight loss vs 15% for competitors. 16x P/E, risk/reward favors upside.
Read full article (2 min)